Table 1.

Human FA cancer cell models

Cell lineTissueGene defectOrigin of null stateAvailable controlsLimitationsRef.
RKO FANCC−/−Colorectal adenocarcinomaFANCC (homozygous Δexon 10)Engineered in vitroParental/heterozygote clones (physiologic gene expression)Defect not naturally selected, microsatellite unstable cancer cells(46)
RKO FANCG−/−Colorectal adenocarcinomaFANCG (homozygous Δexon 8)Engineered in vitroParental/heterozygote clones (physiologic gene expression)Defect not naturally selected, microsatellite unstable cancer cells(46)
Hs766TPancreatic adenocarcinomaFANCG (313G>T + LOH*)Somatically acquired in vivoDerivatives overexpressing FANCG or other linesEither gene overexpression or lack of isogenic controls(15, 86)
PL11Pancreatic adenocarcinomaFANCC (homozygous deletion)Somatically acquired in vivoDerivatives overexpressing FANCC or other linesEither gene overexpression or lack of isogenic controls(15, 86)
CAPAN1Pancreatic adenocarcinomaBRCA2 (6174ΔT + LOH*)Somatically acquired in vivoDerivatives overexpressing BRCA2 or other linesEither gene overexpression or lack of isogenic controls(15, 86, 88, 89)
TOV-21GOvarian adenocarcinomaFANCF (epigenetic silencing)UnknownDerivatives overexpressing FANCF or other linesEither gene overexpression or lack of isogenic controls(19)
OHSU-974Head and neck squamous cell carcinomaFANCA?Germ line (i.e., before tumorigenesis)Other linesLack of isogenic controls(100)
VU1365Head and neck squamous cell carcinomaFANCAGerm line (i.e., before tumorigenesis)Derivatives overexpressing FANCA or other linesEither gene overexpression or lack of isogenic controls(100)
VU1131Head and neck squamous cell carcinomaFANCC (67ΔG)Germ line (i.e., before tumorigenesis)Derivatives overexpressing FANCC or other linesEither gene overexpression or lack of isogenic controls(100)
FA-AML1Acute myeloic leukemia cellsBRCA2 (8415G>T, 8732C>A, reverting mutation 8731T>G)Somatically reverted germ line null state during tumorigenesisOther linesNo FA phenotype due to reversion of the null state(101)
SB1690CBAcute myeloic leukemia cellsBRCA2 (3827ΔGT, IVS7 + 2T>G)Germ line (i.e., before tumorigenesis)Other linesLack of isogenic controls(102)
  • * LOH, loss of heterozygosity.

  • Complementation analysis was not conclusive (100).

  • Complementation group was determined by retroviral complementation (100).